Newron Pharmaceuticals S.p.A. (NWRN.SW)
- Previous Close
8.13 - Open
8.40 - Bid --
- Ask 8.11 x --
- Day's Range
7.98 - 8.40 - 52 Week Range
5.20 - 11.20 - Volume
40,859 - Avg. Volume
69,947 - Market Cap (intraday)
162.265M - Beta (5Y Monthly) 0.59
- PE Ratio (TTM)
10.16 - EPS (TTM)
0.79 - Earnings Date Apr 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
17.78
Newron Pharmaceuticals S.p.A., a biopharmaceutical company, discovers and develops novel therapies for patients with diseases of the central and peripheral nervous system in Italy and the United States. It offers Xadago (safinamide), a chemical entity for the treatment of Parkinson's in the European Union, the United Kingdom, the United States, Latin America, Switzerland, and Japan. The company's lead compound includes Evenamide, an add-on therapy for the treatment of Schizophrenia and treatment-resistant schizophrenia, which is in Phase III clinical trial; and Ralfinamide for the treatment of rare neuropathic pain indication. It has a strategic partnership with Zambon and Meiji Seika Pharma Co., Ltd. for the commercialization of safinamide. The company was founded in 1999 and is headquartered in Bresso, Italy.
www.newron.comRecent News: NWRN.SW
View MorePerformance Overview: NWRN.SW
Trailing total returns as of 5/15/2025, which may include dividends or other distributions. Benchmark is MSCI WORLD (^990100-USD-STRD) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NWRN.SW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NWRN.SW
View MoreValuation Measures
Market Cap
162.27M
Enterprise Value
200.44M
Trailing P/E
10.20
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.37
Price/Book (mrq)
118.69
Enterprise Value/Revenue
4.15
Enterprise Value/EBITDA
8.23
Financial Highlights
Profitability and Income Statement
Profit Margin
30.83%
Return on Assets (ttm)
36.44%
Return on Equity (ttm)
--
Revenue (ttm)
51.39M
Net Income Avi to Common (ttm)
15.84M
Diluted EPS (ttm)
0.79
Balance Sheet and Cash Flow
Total Cash (mrq)
9.83M
Total Debt/Equity (mrq)
3,461.52%
Levered Free Cash Flow (ttm)
-26.67M